INT134943

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 10
Disease Relevance 4.23
Pain Relevance 0.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (MOCS1) small molecule metabolic process (MOCS1) nucleus (MOCS1)
Anatomy Link Frequency
liver 1
bone marrow 1
spleen 1
face 1
lungs 1
MOCS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 17 95.28 Very High Very High Very High
metalloproteinase 16 75.28 Quite High
Pain 19 74.08 Quite High
palliative 5 63.56 Quite High
Inflammation 23 37.76 Quite Low
cytokine 22 20.64 Low Low
ischemia 11 8.76 Low Low
cva 15 5.00 Very Low Very Low Very Low
Sciatica 14 5.00 Very Low Very Low Very Low
chemokine 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Gauchers Disease 414 98.44 Very High Very High Very High
Infarction 1 97.16 Very High Very High Very High
Injury 13 95.92 Very High Very High Very High
Apoptosis 38 92.40 High High
Disease 134 91.68 High High
Myocardial Infarction 46 91.40 High High
Necrosis 17 89.52 High High
Renal Disease 1 79.52 Quite High
Death 18 79.00 Quite High
Pressure And Volume Under Development 7 78.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both the 39 and 19 amino acid native GBA signal sequences were capable of endoplasmic reticulum targeting, which led to secretion of the recombinant protein, although approximately 30% more enzyme was produced using the longer signal sequence.
Localization (secretion) of enzyme in reticulum
1) Confidence 0.07 Published 2006 Journal Biochem. Cell Biol. Section Abstract Doc Link 16609695 Disease Relevance 0.53 Pain Relevance 0.07
ISZ [18] approximates more closely the in vivo situation than other techniques and is becoming widely used in oncology [19,20] and musculoskeletal research [21,22] for localizing enzyme activity in human and animal tissues.
Localization (localizing) of enzyme in animal tissues
2) Confidence 0.01 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206387 Disease Relevance 0 Pain Relevance 0
Experiment 2: localization and semiquantification of matrix degrading enzyme expression in sections used for ISZ
Localization (localization) of enzyme
3) Confidence 0.01 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206387 Disease Relevance 0 Pain Relevance 0.04
While in bone marrow, the maximal enzymatic activity is measured at 40–60 minutes.29 The uptake and tissue distribution of radio-labeled recombinant enzyme after a bolus injection was followed in patients with type 1 GD.
Localization (distribution) of enzyme in bone marrow associated with gauchers disease
4) Confidence 0.01 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0.30 Pain Relevance 0.06
increase of enzyme release occurred (data not shown).

3.4.

Localization (release) of enzyme
5) Confidence 0.01 Published 2007 Journal PPAR Research Section Body Doc Link PMC1852897 Disease Relevance 0.50 Pain Relevance 0.16
The vector induced sustained hepatic secretion of the enzyme, which was sufficient to prevent accumulation of glucosylceramide and Gaucher cells in the liver, spleen, and lungs of young animals and had marked benefit on these parameters in older mice with established disease.
Localization (secretion) of enzyme in liver associated with disease
6) Confidence 0.01 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.48 Pain Relevance 0
In the face of this crisis, many physicians and regulatory agencies worked with all the commercial partners to promote release of the new enzyme preparations through compassionate access programs before licensing to expedite the regulatory processes for licensing approval and to accelerate approval for distribution in the United States, Europe, and other regions, wherever possible.


Localization (release) of enzyme in face
7) Confidence 0.01 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.21 Pain Relevance 0
The enzyme is released rapidly (within 4 to 6 hours) into the circulation after the onset of infarction.
Localization (released) of enzyme associated with infarction
8) Confidence 0.01 Published 2008 Journal Crit Care Section Body Doc Link PMC2481437 Disease Relevance 1.26 Pain Relevance 0
The vector induced sustained hepatic secretion of the enzyme, which was sufficient to prevent accumulation of glucosylceramide and Gaucher cells in the liver, spleen, and lungs of young animals and had marked benefit on these parameters in older mice with established disease.
Localization (secretion) of enzyme in lungs associated with disease
9) Confidence 0.00 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.48 Pain Relevance 0
The vector induced sustained hepatic secretion of the enzyme, which was sufficient to prevent accumulation of glucosylceramide and Gaucher cells in the liver, spleen, and lungs of young animals and had marked benefit on these parameters in older mice with established disease.
Localization (secretion) of enzyme in spleen associated with disease
10) Confidence 0.00 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.48 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox